NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis.

Cancers (Basel) · 2024 · PMC11048446 · PMID 38672643

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Thus, among the 81 patients with breast cancer or gynecological malignancies who underwent molecular profiling (11/81, 13.6%) experienced a highly significant clinical improvement (major clinical benefit) through precision oncology.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.